Welcome to our dedicated page for Kiora Pharma SEC filings (Ticker: KPHMW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Kiora Pharma's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Kiora Pharma's regulatory disclosures and financial reporting.
Kiora Pharmaceuticals CFO Melissa Tosca reported a small insider transaction involving company common stock. On July 1, 2026, 911 shares were disposed of at $2.66 per share as a tax-withholding disposition, meaning shares were delivered to satisfy tax obligations rather than sold on the open market. Following this transaction, Tosca directly holds 26,064 shares of Kiora Pharmaceuticals common stock.
Kiora Pharmaceuticals CFO Melissa Tosca reported a small insider transaction involving company common stock. On July 1, 2026, 911 shares were disposed of at $2.66 per share as a tax-withholding disposition, meaning shares were delivered to satisfy tax obligations rather than sold on the open market. Following this transaction, Tosca directly holds 26,064 shares of Kiora Pharmaceuticals common stock.
Kiora Pharmaceuticals' President and CEO Brian M. Strem reported a small share disposition related to taxes. On July 1, 2026, he had 1,869 shares of Kiora common stock transferred at $2.66 per share as a tax-withholding disposition, meaning shares were delivered to cover tax obligations rather than sold on the open market. After this transaction, he directly owns 58,823 common shares, so the adjustment represents a minor change in his overall stake.
Kiora Pharmaceuticals' President and CEO Brian M. Strem reported a small share disposition related to taxes. On July 1, 2026, he had 1,869 shares of Kiora common stock transferred at $2.66 per share as a tax-withholding disposition, meaning shares were delivered to cover tax obligations rather than sold on the open market. After this transaction, he directly owns 58,823 common shares, so the adjustment represents a minor change in his overall stake.
Kiora Pharmaceuticals filed a current report describing new preclinical data for its ion channel modulator platform. The company reported that KIO-300, the active ingredient in its Phase 2 vision restoration drug KIO-301, significantly suppressed seizure-associated electrical activity in an ex vivo temporal lobe epilepsy model.
The effect reduced spontaneous epileptiform event frequency versus vehicle controls and remained during treatment and washout, while broader electrical transmission in brain tissue was preserved. These findings, presented at the Epilepsy Foundation Pipeline Conference, support potential applications of KIO-300 in epilepsy and other neurological disorders beyond ophthalmology.
Kiora Pharmaceuticals filed a current report describing new preclinical data for its ion channel modulator platform. The company reported that KIO-300, the active ingredient in its Phase 2 vision restoration drug KIO-301, significantly suppressed seizure-associated electrical activity in an ex vivo temporal lobe epilepsy model.
The effect reduced spontaneous epileptiform event frequency versus vehicle controls and remained during treatment and washout, while broader electrical transmission in brain tissue was preserved. These findings, presented at the Epilepsy Foundation Pipeline Conference, support potential applications of KIO-300 in epilepsy and other neurological disorders beyond ophthalmology.
Kiora Pharmaceuticals director Carmine N. Stengone received a stock option grant as part of equity compensation. On June 10, 2026, he was awarded options covering 25,000 shares of common stock at an exercise price of $2.63 per share, with no cash paid for the grant itself.
The options were granted under Kiora’s 2024 Equity Incentive Plan and will become fully exercisable on June 10, 2027. They expire on June 10, 2036 if not exercised. After this award, Stengone holds options for 25,000 underlying shares directly, and the filing does not report any open‑market purchases or sales.
Kiora Pharmaceuticals director Carmine N. Stengone received a stock option grant as part of equity compensation. On June 10, 2026, he was awarded options covering 25,000 shares of common stock at an exercise price of $2.63 per share, with no cash paid for the grant itself.
The options were granted under Kiora’s 2024 Equity Incentive Plan and will become fully exercisable on June 10, 2027. They expire on June 10, 2036 if not exercised. After this award, Stengone holds options for 25,000 underlying shares directly, and the filing does not report any open‑market purchases or sales.
Kiora Pharmaceuticals director Aron Shapiro received a grant of stock options as part of equity compensation. The award covers 25,000 options for Common Stock at an exercise price of $2.63 per share, becomes fully exercisable on June 10, 2027, and expires on June 10, 2036.
Kiora Pharmaceuticals director Aron Shapiro received a grant of stock options as part of equity compensation. The award covers 25,000 options for Common Stock at an exercise price of $2.63 per share, becomes fully exercisable on June 10, 2027, and expires on June 10, 2036.
Kiora Pharmaceuticals director Erin Parsons reported a compensation-related stock option grant. She received options to buy 25,000 shares of Kiora common stock at an exercise price of $2.63 per share under the company’s 2024 Equity Incentive Plan.
The options will become fully exercisable on June 10, 2027 and expire on June 10, 2036. After this grant, Parsons holds options covering 25,000 shares. This is an award, not an open-market purchase or sale of stock.
Kiora Pharmaceuticals director Erin Parsons reported a compensation-related stock option grant. She received options to buy 25,000 shares of Kiora common stock at an exercise price of $2.63 per share under the company’s 2024 Equity Incentive Plan.
The options will become fully exercisable on June 10, 2027 and expire on June 10, 2036. After this grant, Parsons holds options covering 25,000 shares. This is an award, not an open-market purchase or sale of stock.
Kiora Pharmaceuticals director David Hollander received a grant of stock options as compensation. He was awarded options covering 25,000 shares of common stock at an exercise price of $2.63 per share, issued under the company’s 2024 Equity Incentive Plan.
The options will become fully exercisable on June 10, 2027 and are scheduled to expire on June 10, 2036 if not exercised. After this grant, Hollander holds 25,000 stock options directly, giving him potential future ownership if the options are exercised.
Kiora Pharmaceuticals director David Hollander received a grant of stock options as compensation. He was awarded options covering 25,000 shares of common stock at an exercise price of $2.63 per share, issued under the company’s 2024 Equity Incentive Plan.
The options will become fully exercisable on June 10, 2027 and are scheduled to expire on June 10, 2036 if not exercised. After this grant, Hollander holds 25,000 stock options directly, giving him potential future ownership if the options are exercised.
Kiora Pharmaceuticals director Lisa Walters-Hoffert received a grant of stock options as part of her compensation. She was awarded 25,000 options to buy Kiora common stock at an exercise price of $2.63 per share under the company’s 2024 Equity Incentive Plan.
The options were granted at no cost and relate to 25,000 underlying shares of common stock. They will become fully exercisable on June 10, 2027 and will expire on June 10, 2036 if not exercised. After this grant, she holds 25,000 options directly, and the filing reports no open-market purchases or sales.
Kiora Pharmaceuticals director Lisa Walters-Hoffert received a grant of stock options as part of her compensation. She was awarded 25,000 options to buy Kiora common stock at an exercise price of $2.63 per share under the company’s 2024 Equity Incentive Plan.
The options were granted at no cost and relate to 25,000 underlying shares of common stock. They will become fully exercisable on June 10, 2027 and will expire on June 10, 2036 if not exercised. After this grant, she holds 25,000 options directly, and the filing reports no open-market purchases or sales.
Kiora Pharmaceuticals director Praveen Tyle received a grant of stock options as equity compensation. The award covers options on 40,000 shares of common stock at an exercise price of $2.63 per share under the 2024 Equity Incentive Plan.
The options become fully exercisable on June 10, 2027 and expire on June 10, 2036. Following this grant, Tyle holds options on 40,000 shares directly, with no open-market buying or selling reported in this filing.
Kiora Pharmaceuticals director Praveen Tyle received a grant of stock options as equity compensation. The award covers options on 40,000 shares of common stock at an exercise price of $2.63 per share under the 2024 Equity Incentive Plan.
The options become fully exercisable on June 10, 2027 and expire on June 10, 2036. Following this grant, Tyle holds options on 40,000 shares directly, with no open-market buying or selling reported in this filing.
Kiora Pharmaceuticals, Inc. is registering 11,797,088 shares of Common Stock for resale by selling stockholders.
The registration covers (i) 438,471 shares issued in a Private Placement, (ii) 1,527,710 shares underlying pre-funded warrants, (iii) 7,864,726 shares underlying Tranche A-1 warrants, and (iv) 1,966,181 shares underlying Tranche A-2 warrants. The Company is not offering any shares for its own account and will receive no proceeds from resales; however, the Company would receive proceeds from any warrant cash exercises. The prospectus states that the registered securities represent approximately 72.7% of outstanding common stock as of May 14, 2026 after giving effect to the registered underlying shares. The resale may occur from time to time through public or private transactions as described in the Plan of Distribution.
Kiora Pharmaceuticals, Inc. is registering 11,797,088 shares of Common Stock for resale by selling stockholders.
The registration covers (i) 438,471 shares issued in a Private Placement, (ii) 1,527,710 shares underlying pre-funded warrants, (iii) 7,864,726 shares underlying Tranche A-1 warrants, and (iv) 1,966,181 shares underlying Tranche A-2 warrants. The Company is not offering any shares for its own account and will receive no proceeds from resales; however, the Company would receive proceeds from any warrant cash exercises. The prospectus states that the registered securities represent approximately 72.7% of outstanding common stock as of May 14, 2026 after giving effect to the registered underlying shares. The resale may occur from time to time through public or private transactions as described in the Plan of Distribution.